MedPath

Role of ultrasound derived kidney index and urine and serum biomarkers in determining the type of kidney injury in patients with liver disease

Not yet recruiting
Conditions
Other and unspecified cirrhosis ofliver, (2) ICD-10 Condition: N179||Acute kidney failure, unspecified,
Registration Number
CTRI/2020/09/027816
Lead Sponsor
Dr Ajay Kumar
Brief Summary

This study is a prospective observational single centre study comparing the diagnostic accuracy of renal resistive index, urine NGAL and serum IL-6 for differentiating the type of acute kidney injury in patients of cirrhosis with acute kidney injury, in 70 patients over 12 months. The primary outcome measure will be differentiating ATN vs Non-ATN AKI on day 3. The secondary outcome measure will be differentiating Pre Renal AKI, HRS-AKI, ATN-AKI on day 3.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
70
Inclusion Criteria

Diagnosed cases of cirrhosis with AKI (≥ Stage IB, Serum creatinine ≥ 1.5mg/dL).

Exclusion Criteria

Hypertension Diabetes Mellitus Renovascular disease CKD Prior Kidney or Liver Tramsplant Acute or Chronic Renal Replacement Therapy at the time of enrolment Other causes of renal insufficiency like intrinsic causes of AKI other than ATN (like glomerulonephritis) or urinary Obstruction Confirmed pregnancy UTI.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Differentiating between ATN(Acute Tubular Necrosis) and Non-ATN AKI(Acute Kidney Injury)3 Days
Secondary Outcome Measures
NameTimeMethod
Differentiating between Pre-renal AKI, HRS(Hepatorenal Syndrome)-AKI, ATN-AKI3 Days

Trial Locations

Locations (1)

G.B. Pant Institute of Postgraduate Medical Education and Research(GIPMER)

🇮🇳

Central, DELHI, India

G.B. Pant Institute of Postgraduate Medical Education and Research(GIPMER)
🇮🇳Central, DELHI, India
Dr Ajay Kumar
Principal investigator
9718599226
ajaykumar.aiims@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.